{
    "body": "Which are the lipid lowering drugs administered in patients with Coronary Artery Disease (CAD)?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23074505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23409830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15174957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19801853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19090788", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23538020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10987597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20574136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10637948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19563393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25934512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15809368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18674471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11113401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11597936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24527682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27923158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18973424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20671371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16098846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25999102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20124992"
    ], 
    "ideal_answer": [
        "The lipid lowering drugs administered in patients with Coronary Artery Disease (CAD) are:\n1) Statins\n2) Fibrates\n3) Resins\n4) Niacin\n5) Cholesterol absorption-inhibiting drugs."
    ], 
    "exact_answer": [
        [
            "Statins"
        ], 
        [
            "Fibrates"
        ], 
        [
            "Resins"
        ], 
        [
            "Niacin"
        ], 
        [
            "Cholesterol absorption-inhibiting drugs"
        ]
    ], 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:3393", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003324", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003327"
    ], 
    "type": "list", 
    "id": "589c42b178275d0c4a00003f", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 193, 
            "text": "Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 544, 
            "offsetInEndSection": 658, 
            "text": "After maximizing statin dose, ezetimibe was added to reach the LDL cholesterol goal in 34% of patients (n\u00a0= 734). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1212, 
            "offsetInEndSection": 1607, 
            "text": "Using Cox regression analysis, the most significant factors associated with achieving LDL cholesterol goals were lower baseline LDL cholesterol, average statin dose, and ezetimibe use. In conclusion, after maximizing statin dose, the addition of ezetimibe results in a substantial increase in the percentage of patients who reach LDL cholesterol goal, a key component of optimal medical therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 129, 
            "text": "Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 297, 
            "text": "Remnant lipoproteinemia is a strong risk factor for cardiovascular (CV) diseases. This study examined which of 2 common lipid-lowering drugs (fibrates and statins) is more effective in patients with remnant lipoproteinemia and if lowering remnant lipoprotein levels can reduce CV risk.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 767, 
            "offsetInEndSection": 896, 
            "text": "RLP-C levels at 1 year of treatment were reduced more by bezafibrate than pravastatin (37% and 25% from baseline, respectively). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1245, 
            "offsetInEndSection": 1438, 
            "text": "Bezafibrate therapy decreased RLP-C levels to a greater extent than pravastatin and a decrease in RLP-C level may be associated with a reduction in CV events in patients with high RLP-C levels.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 116, 
            "text": "Statins are powerful lipid-lowering drugs, widely used in patients with hyperlipidemia and coronary artery disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18973424", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 3479, 
            "offsetInEndSection": 3636, 
            "text": "Patients are frequently treated with lipid-lowering drugs such as resins, fibrates, niacin, statins and cholesterol absorption-inhibiting drugs (ezetimibe). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074505", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 590, 
            "text": "This study sought to investigate the effect of daily glucose fluctuation on coronary plaque properties in patients with coronary artery disease (CAD) pre-treated with lipid-lowering therapy.There is growing evidence that glucose fluctuation, as a residual risk apart from dyslipidemia, is an important factor contributing to the development of CAD.This prospective study enrolled 70 consecutive CAD patients who were referred for percutaneous coronary intervention and whose low-density lipoprotein cholesterol level was &lt;120 mg/dl under statin treatment or &lt;100 mg/dl without statins", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25999102", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 319, 
            "text": "To investigate the impact of lipid lowering therapy by different means on skin microvascular function in patients with dysglycaemia and coronary artery disease (CAD).Thirty-six patients were randomized to simvastatin 80 mg daily (S80, n = 19) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10, n = 17) for 6 weeks", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19563393", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 156, 
            "text": "Large clinical trials have elucidated that lipid-lowering therapy using statins reduces cardiovascular events in patients with coronary artery disease (CAD)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20671371", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 161, 
            "offsetInEndSection": 342, 
            "text": "The aim of the present study was to investigate whether LLT (lipid-lowering therapy) with statins could attenuate EPC telomere erosion in patients with CAD (coronary artery disease)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19090788", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 166, 
            "text": "Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11113401", 
            "endSection": "title"
        }
    ]
}